505 related articles for article (PubMed ID: 10953141)
1. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz B; Schnall M; Schultz D; Cote K; Tomaszewski JE; Wein A
J Urol; 2000 Sep; 164(3 Pt 1):759-63. PubMed ID: 10953141
[TBL] [Abstract][Full Text] [Related]
2. Role of percent positive biopsies and endorectal coil MRI in predicting prognosis in intermediate-risk prostate cancer patients.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Schnall M; Tomaszewski JE; Wein A
Cancer J Sci Am; 1996; 2(6):343-50. PubMed ID: 9166555
[TBL] [Abstract][Full Text] [Related]
3. The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer.
D'Amico AV; Whittington R; Schnall M; Malkowicz SB; Tomaszewski JE; Schultz D; Wein A
Cancer; 1995 May; 75(9):2368-72. PubMed ID: 7536124
[TBL] [Abstract][Full Text] [Related]
4. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Silver B; Henry L; Hurwitz M; Kaplan I; Beard CJ; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
Mol Urol; 2000; 4(3):171-5;discussion 177. PubMed ID: 11062371
[TBL] [Abstract][Full Text] [Related]
6. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer.
D'Amico AV; Wu Y; Chen MH; Nash M; Renshaw AA; Richie JP
J Urol; 2001 Jan; 165(1):126-9. PubMed ID: 11125380
[TBL] [Abstract][Full Text] [Related]
7. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Schnall M; Tomaszewski JE; Wein A
J Urol; 1995 Jul; 154(1):131-8. PubMed ID: 7539857
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Fondurulia J; Chen MH; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
J Clin Oncol; 2000 Mar; 18(6):1164-72. PubMed ID: 10715284
[TBL] [Abstract][Full Text] [Related]
9. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
10. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer.
D'Amico AV; Schultz D; Silver B; Henry L; Hurwitz M; Kaplan I; Beard CJ; Renshaw AA
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):679-84. PubMed ID: 11172949
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of endorectal MRI in determining PSA outcome for patients with biopsy Gleason score 7, PSA Cheng GC; Chen MH; Whittington R; Malkowicz SB; Schnall MD; Tomaszewski JE; D'Amico AV
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):64-70. PubMed ID: 12504037
[TBL] [Abstract][Full Text] [Related]
12. Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Schnall M; Tomaszewski JE; Wein A
Urology; 1997 Mar; 49(3A Suppl):23-30. PubMed ID: 9123732
[TBL] [Abstract][Full Text] [Related]
13. A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Schnall M; Tomaszewski J; Schultz D; Kao G; VanArsdalen K; Wein A
Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):293-302. PubMed ID: 7928457
[TBL] [Abstract][Full Text] [Related]
14. Optimizing patient selection for prostate monotherapy.
Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
[TBL] [Abstract][Full Text] [Related]
15. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
16. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Wu YH; Chen M; Art M; Tomaszewski JE; Wein A
Urology; 2000 Apr; 55(4):572-7. PubMed ID: 10736506
[TBL] [Abstract][Full Text] [Related]
17. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
18. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate.
D'amico AV; Tempany CM; Schultz D; Cormack RA; Hurwitz M; Beard C; Albert M; Kooy H; Jolesz F; Richie JP
Urology; 2003 Dec; 62(6):1063-7. PubMed ID: 14665356
[TBL] [Abstract][Full Text] [Related]
19. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy.
Freedland SJ; Csathy GS; Dorey F; Aronson WJ
Urology; 2002 Jul; 60(1):84-8. PubMed ID: 12100929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
